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Abstract 22 
Nonsyndromic Cleft Lip and/or Palate (NSCLP) is regarded as a multifactorial condition in 23 
which clefting is an isolated phenotype, distinguished from the largely monogenic, syndromic 24 
forms which include clefts among a spectrum of phenotypes. Nonsyndromic clefting has been 25 
shown to arise through complex interactions between genetic and environmental factors. 26 
However, there is increasing evidence that the broad NSCLP classification may include a 27 
proportion of cases showing familial patterns of inheritance and contain highly penetrant 28 
deleterious variation in specific genes. Through exome sequencing of multi-case families 29 
ascertained in Bogota, Colombia, we identify 28 non-synonymous single nucleotide variants 30 
that are considered damaging by at least one predictive score. We discuss the functional 31 
impact of candidate variants identified. In one family we find a coding variant in the MSX1 32 
gene which is predicted damaging by multiple scores. This variant is in exon 2, a highly 33 
conserved region of the gene. Previous sequencing has suggested that mutations in MSX1 34 
may account for ~2% of NSCLP. Our analysis further supports evidence that a proportion of 35 
NSCLP cases arise through monogenic coding mutations, though further work is required to 36 
unravel the complex interplay of genetics and environment involved in facial clefting. 37 
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Introduction 44 
Cleft lip and/or palate (CLP) phenotypes are among the most frequent birth defects occurring 45 
at rates of 1/500-1/2500 births 1. A proportion of cases present with syndromic disease (CLP 46 
in addition to a spectrum of additional phenotypes) mostly caused by rare mutations in single 47 
genes that often show Mendelian patterns of inheritance. However up to 70% of cases show 48 
phenotypes lacking any additional cognitive or craniofacial abnormalities, referred to as 49 
nonsyndromic cleft lip and/or palate (NSCLP). Such phenotypes are regarded as genetically 50 
complex arising through the interplay of numerous genetic and environmental factors. 51 
Increased understanding of the underlying aetiology of NSCLP phenotypes (both genetic and 52 
environmental) is needed to ultimately develop strategies for prevention, and improve 53 
treatment and prognosis. NSCLP has a significant genetic basis, for example, the first degree 54 
relatives of affected individuals have a 30–40 fold elevated risk and phenotype concordance 55 
for monozygotic (MZ) twins is 40–60%, compared to 5% for di-zygotic twins 1. Genetic 56 
studies including linkage analysis, genome-wide association (GWAS), and GWAS-based 57 
meta-analysis, have yielded reproducible evidence for the involvement of several genes and 58 
gene regions. Collins et al., 2 listed 16 genes and gene regions which have been firmly 59 
implicated in NSCLP through linkage and association analysis. Several of these are broad 60 
regions where the underlying causal variant(s) have yet to be pinpointed, however, 61 
polymorphisms in genes such as IRF6 are strongly associated with NSCLP 3 and more minor 62 
roles have been established for MSX1 4,5, PVRL1, FGFR2, PAX7, NOG and SPRY2 among 63 
others 6.  64 
Exome sequencing presents opportunities to identify rare coding variation that may 65 
contribute to risk of NSCLP phenotypes. If NSCLP is entirely multifactorial, the contribution 66 
of rarer variants may be largely polygenic and mediated by numerous variants of very small 67 
individual effect. In this case, causal genes may only be detectible through the analysis of 68 
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large numbers of patients using, for example, burden tests 7. However, there is growing 69 
evidence for involvement of rare variants of larger effect in NSCLP including, for example, 70 
truncating mutations in the ARHGAP29 gene 8 and mutations in the IRF6 gene, which is also 71 
known to contain mutations involved in malformation syndromes that include CLP such as 72 
Van der Woude 9. We consider here a number of NSCLP families with multiple affected 73 
individuals and undertake exome sequencing to investigate the contribution of rare variants in 74 
genes previously associated with any form of clefting phenotype.  75 
Materials and Methods 76 
Exome sequences of twelve individuals from seven multi-case families (CL1-CL7) with 77 
NSCLP phenotypes were obtained. All experimental protocols were approved by the 78 
Research Ethics Committee at the Universidad de La Sabana, Bogota; informed consent was 79 
obtained for all participants and research was conducted in accordance with the Declaration 80 
of Helsinki. Families included between two and six individuals with isolated NSCLP (Figure 81 
1). Most individuals have unilateral CLP but several individuals have the more severe 82 
bilateral phenotype.  83 
DNA samples were extracted from blood collected at Operation Smile, Bogota, Colombia 84 
and exomes were captured using the Agilent SureSelect v5 (51 Mb) kit and sequenced on a 85 
HiSeq 2000. Read depth coverage statistics for all 12 exome sequences are given in 86 
Supplementary Table 1, and indicate ~85-97% coverage of exon targets at >20 fold depth 87 
across all samples. Orthogonal genotyping was performed for a panel of 24 SNPs to validate 88 
sample identity after processing 10. 89 
To understand the spectrum of potentially damaging variation, we considered the list of 865 90 
genes previously implicated in any form of CLP phenotype presented by Pengelly et al. 11 91 
(Supplementary Table 2) . Examining rare variation in genes in this comprehensive list 92 
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enables evaluation of whether known CLP genes contain variation which may underlie more 93 
familial forms of NSCLP. Furthermore, because each exome contains a very large number of 94 
putatively damaging variants including those completely unrelated to the clefting phenotypes 95 
(including potential incidental findings), this strategy focussing only on genes previously 96 
implicated in any form of clefting is a practical route to identifying causal variation in these 97 
families. The list is derived in part (363 genes out of the 865) from the professional Human 98 
Gene Mutation Database 12, using search terms related to clefts and clefting syndromes. The 99 
remaining genes in the list were included after corresponding interrogation of OMIM 13, and 100 
a small number of additional CLP-related genes from the review by Collins et al.2.  101 
We filtered the lists of variants (Figure 2) found in the exome sequences to identify all non-102 
synonymous (NS), stopgain, stoploss, splicing and indel variants in genes from this list. 103 
Following Pengelly et al.11, for NS variants we used the scaled predictive scores from 104 
dbNSFP v2 14 and considered only variants classed as deleterious or damaging by at least one 105 
of the following predictive metrics: PhyloP, SIFT, Polyphen2, LRT, MutationTaster and 106 
GERP++. Grantham scores were also assigned to all NS substitutions. All variants were 107 
annotated with the minor allele frequency (MAF) from the ExAC database 15, combined 108 
CADD and Logit scores for deleteriousness, along with a combined overall rank developed 109 
from PhylopP, GERP++, CADD and Logit scores based on the summed ranks across all four 110 
scores such that a variant with overall rank 1 is predicted as most deleterious. For intronic 111 
variants within 10 bp of the exon we utilised MaxEntScan, based upon quantifying deviation 112 
from the expected splicing consensus sequence motif, to evaluate the likelihood of this 113 
variant affecting splicing, using a cutoff of a differential score of 3 16.  114 
We excluded variants found in homopolymer/repeat regions that can arise through 115 
misalignment between the sequenced reads and reference sequence. Any variants with read 116 
depth of <10 or in genes considered to be ‘highly mutable’ 17 were removed from further 117 
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consideration. We included all variants not previously listed in the following databases: 118 
dbSNP 135 18, 1000 genomes 19, the exome variant server 20 and our in-house database of 119 
~300 exomes, but did not exclude variants present solely at low frequency in the ExAC 120 
database 15. In Tables 1 & 2 we included only variants found in all exome-sequenced, 121 
affected, family members but not shared by more than one family; this was to exclude 122 
variants potentially common to the region not captured in the population resequencing 123 
projects. Because samples were not available for all family members, it was not possible to 124 
confirm segregation of putatively causal variants for all affected individuals. All variants 125 
presented in text were manually visualised to evaluate genotype quality in the raw alignment 126 
files using IGV 21, and no features consistent with errors were present yielding high-127 
confidence genotype calls . The full list of rare (< 1% in 1000 Genomes) NS variants classed 128 
as damaging by at least one predictive score and potentially damaging splicing variants are 129 
given in Supplementary Table 3. Whole-exome genotype calls are provided in Supplementary 130 
File 4. 131 
Results 132 
Table 1 shows likely protein truncating and indel variants in these seven families, with Table 133 
2 listing 28 missense variants. For a given family only variants found for all the exome-134 
sequenced family members (Figure 1) and classed as deleterious by at least one predictive 135 
score is given. Table 2 entries are ordered using combined ranks from most to least 136 
deleterious by predictive score 11. Four of the genes listed in Table 2 (WNT7A, MSX1, 137 
CLPTM1 and EVC2, ranked 9, 10, 11 and 23 respectively) have been previously identified as 138 
containing variants implicated in NSCLP phenotypes. Family CL1 has the 9th ranked variant 139 
in the WNT7A gene. Members of the WNT gene family have previously been associated with 140 
NSCLP phenotypes 22–24. Specifically, a number of WNT signalling pathway genes including 141 
WNT3A, WNT5A, WNT9B, and WNT11 have been established as candidates 22 and mouse 142 
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expression studies have shown roles for WNT genes in mid-facial formation and lip and 143 
palate development 25.  144 
The 10th ranked variant, found in family CL4, is in the MSX1 gene, and considered damaging 145 
by SIFT, PolyPhen-2 and MutationTaster and has high GERP++ and CADD scores. Variants 146 
in this gene have been strongly implicated in NSCLP in several studies. Jezewski et al. 26 147 
found mutations in 2% of CLP cases and indicated that this has genetic counselling 148 
implications where autosomal dominant inheritance patterns are found. Exon 2 of MSX1, in 149 
which the p.P260T is located, has been found to be highly conserved with significantly fewer 150 
sequence variants compared with exon 1 of this small (two exon) gene 26. Functional 151 
validation of MSX1 as a candidate is established through a cleft palate and foreshortened 152 
maxilla phenotype in knockout mice 27. A number of association studies have also indicated 153 
involvement of MSX1 in NSCLP 4,28–31. In a study of 94 patients and 93 controls from 154 
Operation Smile, Colombia, four MSX1 microsatellite alleles were analysed and an increased 155 
risk of CLP was observed with CA polymorphisms in the gene 32. An autosomal dominant 156 
MSX1 mutation in a family with clefting and tooth agenesis showed a familial pattern of 157 
segregating MSX1 mutations 5. Diverse evidence establishes that MSX1 promotes growth and 158 
inhibits differentiation. Mutations in MSX1 can cause primary or secondary facial clefting in 159 
mouse models 26. 160 
The 11th ranked variant (from family CL1) is in the CLPTM1 gene (Cleft lip-and palate-161 
associated transmembrane protein-1) which is situated at 19q13.3. A balanced translocation is 162 
this region was found in a multi-case CLP family 33 and this region is implicated in NSCLP 163 
by linkage and transmission disequilibrium test association studies 34. However a de novo 164 
deletion of 0.8 Mb in this region associated with CLP, but not encompassing CLPTM1, has 165 
been reported 35. As Kohli and Kohli 36 indicate, the role of CLPTM1 or other genes in this 166 
locus is uncertain.  167 
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The 23rd ranked variant is in the EVC2 gene (family CL2) and belongs to the same two 168 
megabase chromosomal region as MSX1 (4p16). Ingersoll et al. 37 found linkage and 169 
association signals in genes in this region. They found suggestive evidence for linkage and 170 
association amongst cleft palate trios to EVC2. Mutations in EVC2 can lead to Weyers 171 
acrofacial dysostosis 38, not usually associated with oral clefts but cases with subtle CLP 172 
phenotypes, and tooth anomalies have been reported 37.  173 
Discussion 174 
Linkage, candidate gene association and genome-wide association (GWAS) have been 175 
applied to investigate numerous multifactorial diseases, including NSCLP. As a result of 176 
these studies more than 11 genes and gene regions are now known or likely to have an 177 
etiologic role in NSCLP 39. However, there is increasing evidence that NSCLP is a 178 
heterogeneous condition comprising a substantial multifactorial component along with a 179 
much smaller proportion of cases showing more Mendelian patterns of inheritance. The 180 
Gajdos et al. 40 segregation analysis indicated that the complex familial patterns observed in 181 
NSCLP is best explained as a mixture of monogenic cases, probably dominantly inherited, 182 
combined with others which have a multifactorial aetiology. The conclusions favour analyses 183 
of multiple-case pedigrees to reduce heterogeneity and help identify Mendelian sub-forms. 184 
Stanier and Moore 41 identified significant overlaps between genes underlying syndromic and 185 
nonsyndromic forms of CLP, recognising that several genes implicated in syndromic disease, 186 
including TBX22, PVRL1, IRF6, P63 and MSX1, can also contribute to ~10% of NSCLP. 187 
Scapoli et al.42 point out that the autosomal dominant Van der Woude syndrome (VWS) is 188 
only phenotypically distinguished from NSCLP by lower-lip pits and hypodontia which are 189 
only variably present in VWS affected individuals. Mutations in the IRF6 gene, which cause 190 
VWS, have been firmly implicated in some NSCLP cases 3 supporting heterogeneity with the 191 
NSCLP clinical designation. Furthermore, Kerameddin et al.43 found a tag SNP (rs642961) in 192 
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IRF6 was associated with the most severe complete bilateral NSCLP phenotype. This 193 
suggests multi-case families with bilateral clefts are the most likely to be segregating single 194 
gene mutations. This strategy is supported by Vieira et al.44 who indicate that point mutations 195 
in several genes contribute to ~6% of NSCLP, and these are enriched in cases with bilateral 196 
clefting.  197 
In Table 2, we identify a coding variant in the MSX1 gene shared by affected family members 198 
in CL4 in which the proband has a bilateral CLP phenotype. Direct sequencing of coding 199 
regions has shown rare mutations in MSX1 may account for ~2% of NSCLP. The identified 200 
MSX1 variant is present at low frequency in the ExAC database (Table 2). ExAC 201 
contains >60,000 exomes from various disease specfic and population genetic studies 202 
(http://exac.broadinstitute.org/). Functional studies and analyses of larger cohorts of multi-203 
case NSCLP families are required to establish a possible role for this and other rare variants 204 
identified in NSCLP phenotypes. Variants identified here also include candidates in the 205 
WNT7A (family CL1) , CLPTM1 (family CL1) and EVC2 genes (family CL2) which should 206 
be considered as targets for analysis in additional families.  207 
For investigations aiming to resolve the genetic factors underlying NSCLP in multiple case 208 
families, exome sequencing presents a relatively cost-effective approach in which sequencing 209 
a small number of affected family members can identify candidate underlying genetic 210 
variation. NSCLP provides a particular challenge for genetic studies, with incomplete 211 
penetrance and environmental factors hindering the identification of aetiological variance 2,39. 212 
We have aimed to minimise this effect by careful selection of pedigrees exhibiting clefting in 213 
multiple individuals, where we would expect a stronger genetic component. Filtering power 214 
would be increased by the inclusion of further members of the pedigrees, however this has 215 
not been viable due to the isolated geographic locations for many individuals. 216 
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Exome sequencing yields thousands of variants per individual and identification of candidate 217 
variants can only be achieved following extensive filtering. We have undertaken filtering to 218 
identify variants predicted as damaging by restricting analysis to a list of 865 genes which 219 
have been previously associated with any condition involving CLP. Such an approach risks 220 
missing causal variants in novel genes not previously linked to NSCLP, but facilitates 221 
practicable data interpretation by virtue of the greater prior probability that they are 222 
associated with NSCLP. The composite score based rank using PhyloP, GERP++. CADD and 223 
logit (Table 2) has been used successfully prioritise variants involved in syndromic CLP 11, 224 
These four scores are closely correlated, although the composite measures are not 225 
independent in every case. Further improvements in predictive tools and recognition of more 226 
disease variants and understanding of disease pathways will enable future improvements in 227 
interpretation of these complex data sets.  228 
Whilst predictive tools are essential for the prioritisation of variants discovered in next 229 
generation sequencing (NGS) studies, ultimately functional validation of the effects of 230 
variants on protein function is required to confirm their impact. Given the volume of 231 
potentially pathogenic variants being identified in NGS studies, routine functional validation 232 
is infeasible. In silico protein modelling approaches may also be used to improve throughput, 233 
however these require the prior determination of protein structure, which has not been 234 
reported in the majority of genes discussed herein. Overall, it is clear that functional 235 
validation is a significant bottleneck in NGS studies, and one not readily assuaged. 236 
The limitations of exome sequencing include lack of coverage outside gene coding regions 237 
thereby excluding regulatory variants, which may influence risk. Technical limitations 238 
include poor coverage of some coding regions thereby missing potential causal variants. 239 
Whole genome sequencing offers a solution to these coverage issues, but at higher cost and 240 
considerably increased analytical complexity. Given the extent of the missing heritability in 241 
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CLP, it is likely non-coding regions of the genome play a significant role; whole genome 242 
sequencing may therefore provide a valuable tool as sequencing costs continue to drop.  243 
In this study we have limited our analyses to 865 genes with a known/suspected involvement 244 
in CLP phenotypes. Whilst this will prevent us from identifying novel aetiological genes, 7 245 
families would be underpowered to identify novel causal genes reliably. Large cohort studies 246 
are required in order to identify novel CLP genes; to this end we have made our WES data 247 
available in Supplementary File 4 for the use of other researchers.  248 
In conclusion, we have undertaken exome analysis in seven Colombian families with NSCLP 249 
phenotypes. We find a deleterious variant in the MSX1 gene in family CL4 which is a strong 250 
candidate for causality. Deleterious variants in at least three additional genes may be 251 
implicated in NSCLP phenotypes in some of the other families. Although NSCLP is 252 
primarily a complex multifactorial phenotype, our study adds to the growing body of 253 
evidence that Mendelian sub-forms exist and these are best studied in multi-case families 254 
particularly where there are more severe phenotypic features such as bilateral clefting.  255 
 256 
  257 
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Figure legends 381 
Figure 1. Pedigrees of families analysed. + symbol indicates that the individual has been exome 382 
sequenced (sequenced cases: two families with one family member; two families with parent and 383 
offspring; two families with sib pair; one family with avuncular pair). 384 
 385 
Figure 2. Variant filtering process. Variants identified in patients were filtered as described in 386 
methods. Variant attrition at each step is shown here, with variants remaining after sequential 387 
filtering detailed in square brackets. 388 
 389 
390 
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Table 1. Protein truncating, splicing and indel variants observed in single families 











































































































8 8 923_925del 308_309del nonframeshift_deletion - .    ◊    




3 NM_018117 21 2660_2662del 887_888del nonframeshift_deletion - .   ◊     






n - . ◊       
FBLN1 22:45927140 NM_001996 5 485-5C>-  splicing - 22 ◊       
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WDR35 2:20137643 NM_001006657 20 C2161T R721C 4.1E-05 0.00 0.92 1.00 180 9.81 5.04 27.70 0.13 1 ◊       
PTHLH 12:28122357 NM_002820 3 G71A G24E - 0.00 1.00 0.99 98 5.75 5.13 32.00 0.39 2  ◊      
GPC6 13:94482686 NM_005708 3 T599A F200Y - 0.00 0.98 0.95 22 7.65 5.48 31.00 0.06 3 ◊       
INPPL1 11:71939494 NM_001567 3 G349A V117I - 0.00 0.95 0.04 29 8.18 3.90 22.80 0.11 4 ◊       
MYH3 17:10539158 NM_002470 29 G3869A R1290H 3.3E-05 0.00 0.10 0.94 29 4.95 4.84 21.30 0.13 5    ◊    
AHDC1 1:27876631 NM_001029882 6 C1996G R666G 8.6E-06 0.00 1.00 0.06 125 8.73 5.08 22.80 0.04 6  ◊      
ABCA12 2:215928852 NM_173076 3 C254T T85I - 0.99 0.73 0.00 89 4.18 5.30 15.26 0.10 7   ◊     
DEAF1 11:654023 NM_021008 11 C1532G A511G - 0.00 0.59 1.00 60 9.01 3.03 17.71 0.08 8   ◊     
WNT7A 3:13860472 NM_004625 4 G1019A S340N - 0.00 0.94 0.99 46 6.07 4.11 23.60 0.06 9 ◊       
MSX1 4:4864736 NM_002448 2 C778A P260T 1.3E-04 0.00 0.61 0.99 38 5.96 4.76 27.60 0.04 10    ◊    
CLPTM1 19:45491357 NM_001294 9 A1058G N353S 8.2E-06 0.04 0.60 0.99 46 6.60 3.01 17.19 0.09 11 ◊       
IGF1R 15:99500597 NM_000875 21 C4030G Q1344E - 0.00 0.01 0.99 29 4.78 5.24 13.05 0.04 12 ◊       
CFDP1 16:75429103 NM_006324 5 A535T T179S - 0.00 0.02 0.99 58 2.66 5.54 15.68 0.04 13 ◊       
NBAS 2:15651437 NM_015909 10 G784A G262S - 0.01 0.09 0.86 56 4.26 4.15 13.81 0.07 14 ◊       
COL17A1 10:105795306 NM_000494 49 T3434C I1145T 1.9E-05 0.00 0.15 0.31 89 5.46 4.39 12.18 0.06 15     ◊   
CDON 11:125887051 NM_001243597 6 A860G N287S - 0.00 0.34 0.64 46 3.10 5.01 15.32 0.04 16       ◊ 
SNAP29 22:21224814 NM_004782 2 A427G N143D - 0.02 0.34 0.17 23 8.77 3.70 11.41 0.04 17  ◊      
NOTCH2 1:120509101 NM_001200001 9 G1465T V489L - 0.00 0.08 0.34 32 0.87 5.38 12.51 0.05 18    ◊    
MASP1 3:186937872 NM_001879 16 G2087A G696E 1.7E-05 0.05 0.09 0.37 98 1.65 3.75 14.53 0.06 19      ◊  
FREM2 13:39263993 NM_207361 1 A2512G T838A 8.2E-06 0.00 0.00 1.00 58 2.49 4.44 7.38 0.07 20    ◊    
SPRY4 5:141693887 NM_030964 3 C856T R286C 2.5E-05 0.00 0.88 0.97 180 2.44 4.70 13.49 0.04 21   ◊     
ZBTB24 6:109802863 NM_001164313 2 A367G K123E - 0.00 0.05 0.32 56 1.52 4.16 14.67 0.03 22    ◊    
EVC2 4:5617202 NM_001166136 16 G2536A E846K 1.6E-05 0.10 0.67 0.27 56 1.14 2.85 16.13 0.03 23  ◊      
SCN2A 2:166187894 NM_001040143 13 T2204C M735T - 0.04 0.00 0.06 81 0.47 2.35 2.95 0.04 24   ◊     
RYR1 19:38976754 NM_000540 34 G5459T R1820L - 0.04 0.01 0.71 102 0.93 1.71 8.87 0.03 25     ◊   
WT1 11:32456755 NM_024426 1 C137T A46V - 0.02 0.00 0.00 64 0.33 0.81 12.21 0.02 26    ◊    
INPPL1 11:71949096 NM_001567 27 T3563G L1188R 1.0E-05 0.10 . 0.01 102 0.44 1.47 10.20 0.01 27 ◊       
COL6A2 21:47551876 NM_001849 28 G2470A V824M 2.9E-04 0.00 . 1.00 21 . 3.62 . . -     ◊   
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◊ = Heterozygous variant observed for all family members sequenced 
Underlined predictive scores damaging by at least one of: SIFT < 0.05 (variant considered to affect protein function); PolyPhen-2 HumVar scores >0.447 
(variant possibly damaging) and >= 0.909 (variant probably damaging); MutationTaster scores >0.95 (variant considered damaging); Grantham scores >100 








CLP - left 
CLP - right
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